2012
DOI: 10.1115/1.4007182
|View full text |Cite
|
Sign up to set email alerts
|

Simulation Based Design and Evaluation of a Transcatheter Mitral Heart Valve Frame

Abstract: In certain populations, open heart surgery to replace a diseased mitral valve is not an option, leaving percutaneous delivery a viable alternative. However, a surgical transcatheter based delivery of a metallic support frame incorporating a tissue derived valve puts considerable constraints on device specifications. Expansion to a large diameter from the catheter diameter without mechanical fracture involves advanced device design and appropriate material processing and selection. In this study, a new frame co… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 29 publications
0
2
0
Order By: Relevance
“…This includes many of the leading TMVs currently in clinical trials, such as Intrepid (Medtronic, Dublin, Ireland), Tendyne (Abbott Laboratories, Chicago, IL) and Tiara (Neovasc, Richmond, Canada), as well as various earlier-stage stent concepts. 7,16 Effective stent design to achieve targeted levels of annular oversizing likely must account for the observed dynamics of this broader tissue region.…”
Section: Discussionmentioning
confidence: 99%
“…This includes many of the leading TMVs currently in clinical trials, such as Intrepid (Medtronic, Dublin, Ireland), Tendyne (Abbott Laboratories, Chicago, IL) and Tiara (Neovasc, Richmond, Canada), as well as various earlier-stage stent concepts. 7,16 Effective stent design to achieve targeted levels of annular oversizing likely must account for the observed dynamics of this broader tissue region.…”
Section: Discussionmentioning
confidence: 99%
“…In recent years, transcatheter mitral valve implantation (TMVI) related to the development of such type bioprostheses is growing dramatically. More than 10-year TMVI development delaying from TAVI is due to complex mitral valve anatomy [2][3][4]. Currently, the main efforts are aimed to design bioprostheses and delivery systems for their implantation in a native mitral valve.…”
Section: Advanced Researchesmentioning
confidence: 99%